Table 7.
Treatments 1 | Item 2 | ||||||||
---|---|---|---|---|---|---|---|---|---|
ADA (U/L) | AST (U/L) | ALT (U/L) | Apo B (ng/mL) | LCAT (ng/mL) | Total Chol (ng/mL) | PLTP (ng/mL) | Free Chol (ng/mL) | G6PDH (mU/mL) | |
MT | 46.22 ± 12.54 | 227.06 ± 8.28 | 7.01 ± 2.39 | 95.49 ± 16.49 | 0.7 ± 0.04 | 11.44 ± 0.82 | 1.48 ± 0.59 | No data 3 | 28.6 ± 1.23 |
MT + 0.025% YCWE | 53.16 ± 6.25 | 248.54 ± 37.90 | 12.8 ± 2.00 | 118.5 ± 51.06 | 0.76 ± 0.00 | 9.91 ± 0.71 | 1.64 ± 1.46 | No data | 30.19 ± 0.87 |
MT + 0.05% YCWE | 45.66 ± 5.67 | 239.16 ± 23.62 | 6.06 ± 2.36 | 80.5 ± 13.00 | 0.70 ± 0.02 | 10.87 ± 0.74 | 3.06 ± 2.88 | No data | 31.47 ± 0.82 |
MT + 0.1% YCWE | 45.94 ± 3.09 | 212.98 ± 23.27 | 7.21 ± 2.22 | 81.27 ± 15.14 | 0.77 ± 0.09 | 9.82 ± 0.63 | 3.86 ± 1.67 | 22.8 ± 0.00 | 30.48 ± 0.88 |
MT + 0.2% YCWE | 50.39 ± 10.47 | 284.96 ± 42.74 | 7.2 ± 3.38 | 101.72 ± 13.57 | 0.67 ± 0.01 | 11.05 ± 0.18 | 1.87 ± 0.97 | No data | 28.89 ± 2.71 |
MT + 0.4% YCWE | 41.5 ± 11.09 | 206.19 ± 14.39 | 6.02 ± 2.05 | 93.72 ± 27.67 | 0.51 ± 0.07 | 11.66 ± 0.81 | 3.13 ± 2.14 | 63.85 ± 0.00 | 29.3 ± 1.16 |
Treatment p-Values | |||||||||
Main effect | 0.951 | 0.433 | 0.417 | 0.913 | 0.061 | 0.344 | 0.906 | No data | 0.723 |
Polynomial Contrast p-Values | |||||||||
Linear | 0.589 | 0.651 | 0.357 | 0.927 | 0.006 | 0.245 | 0.669 | No data | 0.633 |
Quadratic | 0.721 | 0.199 | 0.827 | 0.841 | 0.208 | 0.341 | 0.790 | No data | 0.794 |
Cubic | 0.761 | 0.223 | 0.964 | 0.575 | 0.545 | 0.218 | 0.338 | No data | 0.171 |
1 MT: diet containing mycotoxins; MT + 0.025% YCWE; MT + 0.05% YCWE; MT + 0.1% YCWE; MT + 0.2% YCWE; and MT + 0.4% YCWE; 2 ADA: adenosine deaminase; AST: aspartate aminotransferase; ALT: alanine aminotransferase; Apo B: apolipoprotein B; LCAT: lecithin cholesterol acyltransferase; Total Chol: total cholesterol; PLTP: plasma phospholipid-transfer protein; Free Chol: free cholesterol; G6PDH: glucose 6-phosphate dehydrogenase; 3 No data: readings were out of range causing data to be unavailable.